…
Lunai Bioworks Inc., a pre-clinical stage biotechnology company, provides medicine, diagnostics, and biodefense products the United States and the Netherlands. It operates through three segments, RENB, BioSymetrics, and RENC. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; and RENB-DC20 for the treatment of breast cancer. It also develops an artificial intelligence platform technology for early cancer detection and its recurrence that uses a multi-omics approach to search for individual biomarkers that are present even in asymptomatic patients. The company was formerly known as Renovaro Inc. and changed its name to Lunai Bioworks Inc. in August 2025. Lunai Bioworks Inc. is headquartered in Los Angeles, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Publicly listed on Nasdaq, Lunai Bioworks Inc. is a life sciences company with limited publicly available operational detail; investors should consult company filings and disclosures for specifics. Long-term growth may depend on progress in its research and development, successful regulatory clearances or partnerships, and broader adoption in the biotechnology sector, which could support future revenue expansion and market positioning.
Primary investment risks include limited disclosure and transparency, early-stage or unproven technologies, significant regulatory and financing uncertainty, and likely low liquidity and high volatility in the stock.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
| Income before tax | -178.01M | -88.43M | -39.68M | -113.43M | -26.85M |
| Net income | -178.01M | -88.43M | -39.68M | -113.43M | -26.72M |
| Selling general administrative | 17.88M | 24.56M | 15.32M | 14.33M | - |
| Gross profit | -0.13M | 0.00M | 0.00M | - | -0.39M |
| Reconciled depreciation | 0.13M | 0.12M | 0.11M | 0.12M | - |
| Ebit | -177.28M | -85.99M | -38.98M | -113.06M | -26.47M |
| Ebitda | -177.15M | -85.87M | -38.86M | -112.94M | -26.08M |
| Depreciation and amortization | 0.13M | 0.12M | 0.11M | 0.12M | 0.39M |
| Operating income | -18.55M | -81.64M | -38.56M | -116.08M | -23.40M |
| Other operating expenses | 18.55M | 81.64M | 38.56M | 116.08M | 23.40M |
| Interest expense | 0.73M | 2.43M | 0.71M | 0.37M | 0.38M |
| Tax provision | - | - | 0.00M | 0.00M | - |
| Interest income | 0.12M | - | - | 0.12M | - |
| Net interest income | -0.61M | -2.43M | -0.71M | -0.25M | - |
| Income tax expense | - | - | - | 0.00M | -0.13M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | - |
| Total operating expenses | 18.42M | 81.64M | 38.56M | 116.08M | 23.01M |
| Cost of revenue | 0.13M | - | - | - | 0.39M |
| Total other income expense net | -159.46M | -6.79M | -1.13M | 2.65M | -3.45M |
| Net income from continuing ops | -178.01M | -88.43M | -39.68M | -113.43M | - |
| Breakdown | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
| Total assets | 8.23M | 163.13M | 58.30M | 84.63M | 189.61M |
| Intangible assets | 0.17M | 0.03M | 42.65M | 61.62M | 154.89M |
| Other current assets | 0.57M | 0.67M | 0.69M | 0.39M | 0.23M |
| Total liab | 29.58M | 31.15M | 11.80M | 12.01M | 14.94M |
| Total stockholder equity | -21.35M | 131.98M | 46.50M | 72.62M | 174.66M |
| Other current liab | 6.85M | 17.92M | 0.91M | 3.60M | 1.21M |
| Common stock | 0.02M | 0.02M | 0.01M | 0.01M | 0.01M |
| Capital stock | 0.02M | 0.02M | 0.01M | 0.01M | - |
| Retained earnings | -510.46M | -332.46M | -244.03M | -204.35M | -90.91M |
| Good will | 5.96M | 159.33M | 11.64M | 11.64M | 11.64M |
| Cash | 0.09M | 0.22M | 1.87M | 9.17M | 20.66M |
| Total current liabilities | 29.16M | 30.31M | 11.02M | 6.45M | 1.89M |
| Net debt | 10.08M | 3.57M | 3.72M | -2.16M | -13.29M |
| Short term debt | 9.75M | 2.94M | 4.82M | 1.45M | 0.35M |
| Short long term debt | 9.44M | 2.45M | 4.62M | 1.20M | - |
| Short long term debt total | 10.17M | 3.79M | 5.59M | 7.02M | 7.37M |
| Other stockholder equity | 478.28M | 464.59M | 290.55M | 276.99M | 265.58M |
| Total current assets | 1.05M | 2.00M | 2.57M | 9.57M | 20.90M |
| Short term investments | 0.39M | 0.00M | - | - | - |
| Net receivables | - | 1.11M | - | - | 0.00M |
| Long term debt | - | - | - | 4.58M | - |
| Accounts payable | 12.56M | 9.45M | 5.30M | 1.40M | 0.32M |
| Accumulated other comprehensive income | 10.81M | -0.17M | -0.03M | -0.03M | -0.01M |
| Non currrent assets other | - | 0.02M | 0.02M | 0.07M | 0.02M |
| Non current assets total | 7.18M | 161.13M | 55.74M | 75.07M | 168.71M |
| Capital lease obligations | 0.74M | 1.34M | 0.97M | 1.24M | - |
| Breakdown | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
| Investments | -0.50M | -1.26M | -0.03M | -0.01M | - |
| Total cashflows from investing activities | -0.50M | -1.26M | -0.03M | -0.01M | -0.05M |
| Net borrowings | 6.98M | 8.05M | 0.00M | -0.56M | - |
| Total cash from financing activities | 8.38M | 10.52M | 4.52M | 4.25M | 32.60M |
| Net income | -178.01M | -88.43M | -39.68M | -113.43M | -26.72M |
| Change in cash | -0.13M | -1.65M | -7.30M | -11.49M | 11.97M |
| Begin period cash flow | 0.22M | 1.87M | 9.17M | 20.66M | 8.70M |
| End period cash flow | 0.09M | 0.22M | 1.87M | 9.17M | 20.66M |
| Total cash from operating activities | -7.87M | -10.97M | -11.77M | -15.73M | -20.61M |
| Issuance of capital stock | 2.38M | 3.00M | 4.01M | 4.68M | - |
| Depreciation | 0.13M | 0.12M | 0.11M | 0.12M | 0.39M |
| Change to account receivables | 1.15M | -1.11M | 0.00M | 0.00M | 0.00M |
| Other cashflows from financing activities | -0.97M | -0.53M | 0.50M | 0.13M | 1.22M |
| Capital expenditures | 0.00M | 0.07M | 0.03M | 0.01M | 0.05M |
| Change in working capital | 5.86M | 8.81M | 4.31M | 1.42M | 0.93M |
| Stock based compensation | 3.31M | 4.67M | 3.54M | 5.49M | - |
| Other non cash items | 160.83M | 63.85M | 19.96M | 90.67M | 4.79M |
| Free cash flow | -7.87M | -11.04M | -11.80M | -15.74M | -20.66M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| NVO Novo Nordisk A/S |
-0.54 1.36% |
38.90 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
- -% |
520.66 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
2.34 0.25% |
923.34 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Lunai Bioworks Inc., a pre-clinical stage biotechnology company, provides medicine, diagnostics, and biodefense products the United States and the Netherlands. It operates through three segments, RENB, BioSymetrics, and RENC. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; and RENB-DC20 for the treatment of breast cancer. It also develops an artificial intelligence platform technology for early cancer detection and its recurrence that uses a multi-omics approach to search for individual biomarkers that are present even in asymptomatic patients. The company was formerly known as Renovaro Inc. and changed its name to Lunai Bioworks Inc. in August 2025. Lunai Bioworks Inc. is headquartered in Los Angeles, California.
2080 Century Park East, Los Angeles, CA, United States, 90067
305 918 1980
29
| Name | Title | Year Born |
|---|---|---|
| Mr. David H. Weinstein | CEO & Director | 1961 |
| Mr. Nathen Fuentes CPA | Chief Financial Officer | 1983 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.